Holen Sie sich die Stockscreener-App
2.67
5.53%
0.14
Handel nachbörslich:
2.75
0.08
+3.00%
Nrx Pharmaceuticals Inc Aktie (NRXP) Neueste Nachrichten
NRX-100 and the Fast Track to Market: How NRx Pharmaceuticals Is Revolutionizing Suicide Prevention with FDA-Backed Momentum - AInvest
NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary HOPE Therapeutics(TM) Secures Florida Regulatory Clearance to Close Dura Medical Acquisition - Yahoo Finance
NRx Pharmaceuticals to Report Q2 2025 Results on August 14 - MSN
NRx Pharmaceuticals to Report Q2 2025 Financial Results on August 14, 2025 - AInvest
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Second Quarter 2025 Financial Results Release to August 19, 2025 - BioSpace
NRx Pharmaceuticals: Navigating Regulatory Hurdles and Earnings Delays in the Race for Mental Health Breakthroughs - AInvest
2025-08-13 | NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Second Quarter 2025 Financial Results Release to August 19, 2025 | NDAQ:NRXP | Press Release - Stockhouse
NRx Pharmaceuticals (NASDAQ: NRXP) Petitions FDA to Ban Benzethonium Chloride From Ketamine Products - Yahoo Finance
NRx Pharmaceuticals: A Biotech Company Making Waves with Suicidal Depression Therapies and Clinics - AInvest
From Novel Therapies To Treat Suicidal Bipolar Depression To Launching A Network Of Clinics, NRx Pharmaceuticals Is Getting Attention On Wall Street - NewMediaWire
From Novel Therapies To Treat Suicidal Bipolar Depression To Launching A Network Of Clinics, NRx Pharmaceuticals Is Getting Attention On Wall Street | FinancialContent - FinancialContent
NRx Pharmaceuticals shares fall 5.86% premarket after FDA granted Fast Track designation to NRX-100 for suicidal ideation treatment. - AInvest
Why NRx Pharmaceuticals Inc. stock attracts strong analyst attentionFree Investment Webinars - thegnnews.com
NRx Pharmaceuticals (NASDAQ: NRXP) CEO to Join Fireside Chat at BTIG Virtual Biotechnology Conference - Yahoo Finance
NRx Pharmaceuticals, Inc. Granted FDA Fast Track Designation for NRX-100 for Suicidal Ideation in Patients with Depression, including Bipolar Depression - MarketScreener
NRx Pharmaceuticals shares rise 2.59% premarket after receiving final clearance for Dura Medical acquisition. - AInvest
New to The Street Show #682 Premieres on Bloomberg Tonight Featuring Industry Leaders: DataVault, PetVivo, Health In Tech, FLOKI, and NRx Pharma Backed by National TV Commercials and Outdoor Campaigns Sponsored by MUSQ, ArriveAI, and Sustai - Newport Daily News
Is NRx Pharmaceuticals Inc. Equity Warrant stock a value trapChannel Breakout Watchlist - newsyoung.net
Why Small-Cap Biotech NRx Pharmaceuticals Is Drawing Heavy Retail Buzz - Stocktwits
FDA Grants NRX-100 Fast Track Designation for Suicidal Ideation - HCPLive
$3 Billion Suicidal Depression Market May Soon be Accessible via - openPR.com
$3 Billion Suicidal Depression Market May Soon be Accessible via FDA Fast Track Designation for Effective NRX 100 Drug Therapy: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - Barchart.com
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Second Quarter 2025 Financial Results on August 14, 2025 - GlobeNewswire
NRx Pharmaceuticals (NASDAQ: NRXP) Receives FDA Fast Track Designation for NRX-100 in Treating Suicidal Ideation in Depression - TipRanks
NRx Pharmaceuticals stock price target raised to $21 by BTIG on FDA progress - Investing.com India
FDA Fast Track Designation for NRX-100 for Suicidal Ideation in Patients With Depression, Including Bipolar Depression - Psychiatric Times
FDA grants fast track designation for NRx’s depression treatment By Investing.com - Investing.com Australia
New to The Street Client NRx Pharmaceuticals (NASDAQ:NRXP) Secures FDA Fast Track Designation for NRX-100, Expanding Reach to 13 Million Americans Confronting Suicidal Ideation - ACCESS Newswire
Nrx Pharmaceuticals shares rise 3.17% premarket after FDA granted designation for NRX-100, expanding addressable population. - AInvest
NRx Pharma Receives FDA Fast Track Designation for NRX-100 for Treating Suicidal Ideation in Depression - AInvest
FDA grants fast track designation to NRx for suicidal ideation drug - Investing.com Canada
NRX Pharmaceuticals: D. Boral Capital maintains Buy, PT raised to $31. - AInvest
NRx Pharmaceuticals and the Regulatory Catalysts Reshaping Mental Health Innovation - AInvest
FDA grants NRX-100 "unmet need" designation for treating 13 million Americans with suicidal thoughts. - AInvest
NRx Pharmaceuticals Receives FDA Fast Track Designation for NRX-100 in Treating Suicidal Ideation in Depression Patients - AInvest
FDA Fast Track Breakthrough: NRX-100 Shows 63% Success Rate in Suicidal Depression Treatment - Stock Titan
NRX Pharmaceuticals WRT NRXPW 2025Q2 Earnings Preview Upside Potential on New Product Launch - AInvest
NRX Pharmaceuticals NRXP 2025Q2 Earnings Preview Upside Potential Driven by New Product Launch - AInvest
Is a relief rally coming for NRx Pharmaceuticals Inc. Equity Warrant holdersSmart Stock Forecast Using AI Algorithms - Newser
NRx Pharmaceuticals Inc. stock trend outlook and recovery pathReal Chart Based Opportunity Identification - Newser
Using R and stats models for NRx Pharmaceuticals Inc. forecastingFree Breakout Confirmation With Entry Tracker - Newser
How to recover losses in NRx Pharmaceuticals Inc. Equity Warrant stockAI Stock Movement Forecast with Accuracy - Newser
Can machine learning forecast NRx Pharmaceuticals Inc. recoveryShort-Term Price Breakout Signal Analysis - Newser
Key metrics from NRx Pharmaceuticals Inc.’s quarterly dataPredictable Return Strategy with AI Support - Newser
Combining machine learning predictions for NRx Pharmaceuticals Inc. Equity WarrantGrowth Watchlist for Long Term Positioning - Newser
What machine learning models say about NRx Pharmaceuticals Inc. Equity WarrantFree Smart Trend Trading with Weekly Signals - Newser
Is NRx Pharmaceuticals Inc. stock bottoming outFree Risk Controlled Short Term Trade Plans - Newser
Relative strength of NRx Pharmaceuticals Inc. Equity Warrant in sector analysisTechnical Safety Zone Pattern Recognition - Newser
Bloomberg to Air New to The Street Episode #683 Featuring BioVie, FLOKI, PetVivo, and NRx Pharmaceuticals - AInvest
New to The Street to Air Show #683 on Bloomberg, Featuring BioVie, FLOKI, PetVivo, and NRx Pharmaceuticals - ACCESS Newswire
NRx Pharmaceuticals Receives Final Approval to Acquire Dura Medical, Enhancing Mental Health Services in Florida - AInvest
New Product Launches: Will They Boost NRx Pharmaceuticals Inc. Equity Warrant Stock in 2025Capital Safe Picks with Consistent Gains - Newser
Key resistance and support levels for NRx Pharmaceuticals Inc. Equity WarrantBuy Entry Confirmation Based on Technical Analysis - Newser
Trend analysis for NRx Pharmaceuticals Inc. this weekGrowth Summary Based on Market Positioning - Newser
Can NRx Pharmaceuticals Inc. recover in the next quarterTechnical Insight Guide for Safer Trades - Newser
Multi factor analysis applied to NRx Pharmaceuticals Inc. Equity WarrantBuy Point Strategy with Profit Protection - Newser
Is NRx Pharmaceuticals Inc. showing signs of accumulationFast Movement Forecast for Trading Success - Newser
Technical analysis overview for NRx Pharmaceuticals Inc. stockEntry Optimization Guide with Volume Analysis - Newser
Applying chart zones and confluence areas to NRx Pharmaceuticals Inc.Expert-Backed High Yield Stock Watchlist - Newser
NRx Pharmaceuticals Inc. Equity Warrant Company’s Quarterly Earnings Growth: What the Numbers SayFree Smart Money Tracking Signal Generator - Newser
Nrx Pharmaceuticals shares rise 1.19% after-hours following AHCA approval for Dura Medical acquisition. - AInvest
0.11%
1.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):